The Acorn Saga Continues

Acorn Cardiovascular and Paracor Medical are frequently compared with one another because they are taking similar approaches to treating heart failure. Acorn has gone through a series of setbacks that have slowed its product development, but it's hoping that this third time is the charm. The company reached agreement with the FDA to embark on a 50-patient clinical trial that Acorn hopes leads to agency clearance of its CorCap device. (This is a sidebar to the article, "Paracor: Can a Mechanical Device Treat Heart Failure?")

The company most often compared with Paracor—and its closest competitor--is Acorn Cardiovascular. Such comparisons make sense because the companies are pursuing similar technologies: mechanical devices that wrap around the heart in HF patients to attenuate the progression of heart dilation that causes the organ to grow large and inefficient, unable to pump sufficient amounts of blood. Both companies also hope that their devices can take pressure off the heart to reverse the remodeling process, enabling the organ to heal and get smaller and stronger.

Founded in 1996, three years before Paracor, New Brighton, MN-based Acorn has gone through a series of setbacks that have...

More from Innovation

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.